Ocugen (OCGN) Competitors

Adaptive Biotechnologies (NASDAQ:ADPT) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Does the MarketBeat Community believe in ADPT or OCGN?

Ocugen received 12 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. Likewise, 69.93% of users gave Ocugen an outperform vote while only 57.58% of users gave Adaptive Biotechnologies an outperform vote.

Company	Underperform	Outperform
Adaptive Biotechnologies	Outperform Votes 95 57.58%	Underperform Votes 70 42.42%
Ocugen	Outperform Votes 107 69.93%	Underperform Votes 46 30.07%

Does the media refer more to ADPT or OCGN?

In the previous week, Adaptive Biotechnologies had 4 more articles in the media than Ocugen. MarketBeat recorded 7 mentions for Adaptive Biotechnologies and 3 mentions for Ocugen. Adaptive Biotechnologies' average media sentiment score of 0.92 beat Ocugen's score of 0.47 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocugen	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer ADPT or OCGN?

Adaptive Biotechnologies currently has a consensus target price of $6.75, suggesting a potential upside of 5.63%. Ocugen has a consensus target price of $5.67, suggesting a potential upside of 635.93%. Given Ocugen's stronger consensus rating and higher possible upside, analysts plainly believe Ocugen is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ocugen	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals and insiders hold more shares of ADPT or OCGN?

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 6.2% of Adaptive Biotechnologies shares are owned by insiders. Comparatively, 4.3% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more risk & volatility, ADPT or OCGN?

Adaptive Biotechnologies has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.82, meaning that its share price is 282% more volatile than the S&P 500.

Is ADPT or OCGN more profitable?

Adaptive Biotechnologies has a net margin of -110.13% compared to Ocugen's net margin of -532.51%. Adaptive Biotechnologies' return on equity of -62.06% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-110.13%	-62.06%	-26.82%
Ocugen	-532.51%	-154.75%	-90.79%

Which has preferable valuation and earnings, ADPT or OCGN?

Ocugen has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$177.28M	5.32	-$225.25M	-$1.34	-4.77
Ocugen	$4.70M	47.73	-$63.08M	-$0.18	-4.28

Summary

Ocugen beats Adaptive Biotechnologies on 9 of the 17 factors compared between the two stocks.